Liao Hua, Du Juan, Li Fengjuan, Yang Shiyu, Qi Guanming, Pan Lili
Department of Rheumatology and Immunology, Beijing AnZhen Hospital, Capital Medical University, No. 2 Anzhen Rd., Beijing, 100029, China.
Beijing AnZhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, the Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing, China.
Clin Rheumatol. 2024 Jun;43(6):1979-1987. doi: 10.1007/s10067-024-06957-w. Epub 2024 Apr 10.
The goal of the present study was to investigate the correlation between serum 25-hydroxyvitamin D [25(OH)D] levels and disease remission in Takayasu arteritis (TAK) patients.
This retrospective study included 59 patients in the study group and 80 patients in the validation cohort with TAK. After 6 months of therapy, patients were re-evaluated, and serum 25(OH)D levels were compared before and after treatment. Correlations between changes in 25(OH)D levels and changes in disease activity scores (NIH, ITAS2010, ITAS.A) were analyzed. Additionally, a predictive cut-off value for disease remission was determined.
After 6 months of therapy, serum 25(OH)D levels in TAK patients significantly increased compared to baseline [(18.33 ± 7.25)µg/L vs (11.77 ± 4.14) µg/L] (P < 0.001). Positive correlations were observed between the increasing changes in the 25(OH)D level and the decreasing changes in the reduced NIH, ITAS2010, and ITAS.A scores (r = 0.455, P < 0.001; r = 0.495, P < 0.001; and r = 0.352 P = 0.006, respectively). A change of 8.45 µg/L in 25(OH)D level was identified as the predictive cut-off value for TAK remission (sensitivity 54.1%, specificity 90.9%, area under the curve = 0.741). Similarly for patients with normal baseline ESR, sensitivity is 68.0%, specificity is 92.3%, and area under the curve is 0.831, and for patients with normal baseline CRP, sensitivity is 58.3%, specificity is 90.0%, and area under the curve is 0.748. Validation in an additional 80 patients demonstrated a higher remission rate in those with a 25(OH)D level change > 8.45 µg/L.
Serum 25(OH)D levels significantly increased after treatment in TAK patients, and an increase of ≥ 8.45 µg/L was predictive of disease remission, especially in individuals with normal baseline ESR and/or CRP levels. Key Points • Following treatment, there was a significant increase in serum 25(OH)D levels among TAK patients. • The elevated changes in 25(OH)D levels before and after treatment demonstrated a positive correlation with the reduction in disease activity scores. • In patients with TAK before and after treatment, an elevation in serum 25(OH)D levels exceeding 8.45 µg/L serves as an indicator for disease remission, particularly prominent in individuals with normal baseline ESR and/or CRP levels.
本研究旨在探讨血清25-羟维生素D[25(OH)D]水平与大动脉炎(TAK)患者疾病缓解之间的相关性。
本回顾性研究纳入了59例研究组TAK患者和80例验证队列TAK患者。治疗6个月后,对患者进行重新评估,并比较治疗前后的血清25(OH)D水平。分析25(OH)D水平变化与疾病活动评分(NIH、ITAS2010、ITAS.A)变化之间的相关性。此外,确定疾病缓解的预测临界值。
治疗6个月后,TAK患者的血清25(OH)D水平较基线显著升高[(18.33±7.25)μg/L对(11.77±4.14)μg/L](P<0.001)。25(OH)D水平的升高变化与NIH、ITAS2010和ITAS.A评分的降低变化之间存在正相关(r=0.455,P<0.001;r=0.495,P<0.001;r=0.352,P=0.006)。25(OH)D水平变化8.45μg/L被确定为TAK缓解的预测临界值(敏感性54.1%,特异性90.9%,曲线下面积=0.741)。同样,对于基线血沉正常的患者,敏感性为68.0%,特异性为92.3%,曲线下面积为0.831;对于基线C反应蛋白正常的患者,敏感性为58.3%,特异性为90.0%,曲线下面积为0.748。在另外80例患者中的验证表明,25(OH)D水平变化>8.45μg/L的患者缓解率更高。
TAK患者治疗后血清25(OH)D水平显著升高,升高≥8.45μg/L可预测疾病缓解,尤其是基线血沉和/或C反应蛋白水平正常的个体。要点•治疗后,TAK患者血清25(OH)D水平显著升高。•治疗前后25(OH)D水平的升高变化与疾病活动评分的降低呈正相关。•治疗前后TAK患者血清25(OH)D水平升高超过8.45μg/L可作为疾病缓解的指标,在基线血沉和/或C反应蛋白水平正常的个体中尤为突出。